Publisher
Springer International Publishing
Reference5 articles.
1. Grönroos T, Eskola O, Lethiö K, et al. Pharmacokinetics of [18F]FETNIM, a potential hypoxia marker for PET. J Nucl Med. 2001;42:1397–404.
2. Grönroos TJ, Lehtiö K, Söderström KO, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer. 2014;14:876.
3. Hu M, Zhu Y, Mu D, et al. Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients. Eur J Nucl Med Mol Imaging. 2020;47:1427–34.
4. Lethiö K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:971–82.
5. Tolvanen T, Lehtiö K, Kulmala J, et al. 18F-Fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 2002;43:1674–1680.